Paolo Angeli

List of Publications by Year
in descending order

179 papers	20,316 citations	16451 64 h-index	10734 138 g-index
185 all docs	185 docs citations	185 times ranked	10230 citing authors

#	Article	IF	Citations
1	Towards a new definition of decompensated cirrhosis. Journal of Hepatology, 2022, 76, 202-207.	3.7	66
2	Global hemostatic profiling in patients with decompensated cirrhosis and bacterial infections. JHEP Reports, 2022, 4, 100493.	4.9	17
3	Combined Pharmacological and Endoscopic Treatment for Worsening Gastroesophageal Varices in Patients with Cirrhosis. Clinical and Experimental Gastroenterology, 2022, Volume 15, 59-65.	2.3	1
4	Location and allocation: Inequity of access to liver transplantation for patients with severe acuteâ€onâ€chronic liver failure in Europe. Liver Transplantation, 2022, 28, 1429-1440.	2.4	16
5	EASL International Recognition Awardee 2022: Dr. Pere GinÃ¨s. Journal of Hepatology, 2022, , .	3.7	0
6	Safety, Tolerability, Pharmacokinetics, and Efficacy of Terlipressin Delivered by Continuous Intravenous Infusion in Patients with Cirrhosis and Refractory Ascites. GastroHep, 2022, 2022, 1-8.	0.6	2
7	Endoscopic diode laser therapy for gastric hyperplastic polyps in cirrhotic patients. Lasers in Medical Science, 2021, 36, 975-979.	2.1	3
8	Spontaneous portosystemic shunts in cirrhosis: Detection, implications, and clinical associations. Digestive and Liver Disease, 2021, 53, 1468-1475.	0.9	12
9	Outcomes and Mortality of Grade 1 Ascites and Recurrent Ascites in Patients With Cirrhosis. Clinical Gastroenterology and Hepatology, 2021, 19, 358-366.e8.	4.4	16
10	Clinical features and evolution of bacterial infection-related acute-on-chronic liver failure. Journal of Hepatology, 2021, 74, 330-339.	3.7	76
11	Natural history of acute kidney disease in patients with cirrhosis. Journal of Hepatology, 2021, 74, 578-583.	3.7	32
12	The first year of the new editorial team. Journal of Hepatology, 2021, 74, 5-7.	3.7	0
13	PREDICT identifies precipitating events associated with the clinical course of acutely decompensated cirrhosis. Journal of Hepatology, 2021, 74, 1097-1108.	3.7	149
14	Assessing the role of amino acids in systemic inflammation and organ failure in patients with ACLF. Journal of Hepatology, 2021, 74, 1117-1131.	3.7	45
15	The systemic inflammation hypothesis: Towards a new paradigm of acute decompensation and multiorgan failure in cirrhosis. Journal of Hepatology, 2021, 74, 670-685.	3.7	204
16	Response to Terlipressin and Albumin Is Associated With Improved Liver Transplant Outcomes in Patients With Hepatorenal Syndrome. Hepatology, 2021, 73, 1909-1919.	7.3	53
17	On-treatment serum albumin level can guide long-term treatment in patients with cirrhosis and uncomplicated ascites. Journal of Hepatology, 2021, 74, 340-349.	3.7	38
18	Clinical factors associated with death in 3044 COVID-19 patients managed in internal medicine wards in Italy: results from the SIMI-COVID-19 study of the Italian Society of Internal Medicine (SIMI). Internal and Emergency Medicine, 2021, 16, 1005-1015.	2.0	37

#	Article	IF	Citations
19	Liver Fibrosis and Steatosis in AlstrÃ¶m Syndrome: A Genetic Model for Metabolic Syndrome. Diagnostics, 2021, 11, 797.	2.6	9
20	Bacterial Infections in Cirrhosis as a Cause or Consequence of Decompensation?. Clinics in Liver Disease, 2021, 25, 357-372.	2.1	10
21	Changes in the epidemiology and management of bacterial infections in cirrhosis. Clinical and Molecular Hepatology, 2021, 27, 437-445.	8.9	29
22	New clinical and pathophysiological perspectives defining the trajectory of cirrhosis. Journal of Hepatology, 2021, 75, S14-S26.	3.7	36
23	COVID-19 in liver transplant candidates: pretransplant and post-transplant outcomes - an ELITA/ELTR multicentre cohort study. Gut, 2021, 70, 1914-1924.	12.1	30
24	Reply. Clinical Gastroenterology and Hepatology, 2021, 19, 1510-1511.	4.4	0
25	Untargeted lipidomics uncovers lipid signatures that distinguish severe from moderate forms of acutely decompensated cirrhosis. Journal of Hepatology, 2021, 75, 1116-1127.	3.7	31
26	A step forward in the choice of fluid for early resuscitation of critically ill patients with cirrhosis. Hepatology International, 2021, 15, 858-859.	4.2	1
27	Why have we performed a randomized controlled trial on our own dissemination policy?. Journal of Hepatology, 2021, 75, 261.	3.7	0
28	REPLY:. Hepatology, 2021, 74, 2324-2325.	7.3	0
29	Biomarkers of extracellular matrix formation are associated with acute-on-chronic liver failure. JHEP Reports, 2021, 3, 100355.	4.9	15
30	Low myocardial mechano-energetic efficiency is an independent predictor of prognosis in advanced chronic liver disease. European Journal of Gastroenterology and Hepatology, 2021, 33, e656-e661.	1.6	4
31	Liver transplantation for patients with acute-on-chronic liver failure (ACLF) in Europe: Results of the ELITA/EF-CLIF collaborative study (ECLIS). Journal of Hepatology, 2021, 75, 610-622.	3.7	96
32	Acute-on-Chronic Liver Failure in Cirrhosis. Journal of Clinical Medicine, 2021, 10, 4406.	2.4	9
33	Coronary artery calcium on standard chest computed tomography predicts cardiovascular events after liver transplantation. International Journal of Cardiology, 2021, 339, 219-224.	1.7	8
34	Portal Hypertension and Ascites: Patient-and Population-centered Clinical Practice Guidelines by the Italian Association for the Study of the Liver (AISF). Digestive and Liver Disease, 2021, 53, 1089-1104.	0.9	10
35	Reply to: Correspondence on â€œClinical features and evolution ofÂbacterial infection-related acute-on-chronic liver failureâ€• Journal of Hepatology, 2021, 75, 1010-1012.	3.7	1
36	Prevalence and prognostic value of cirrhotic cardiomyopathy as defined according to the proposed new classification. Clinical and Experimental Hepatology, 2021, 7, 270-277.	1.3	12

#	Article	IF	Citations
37	AISF-SIMTI position paper on the appropriate use of albumin in patients with liver cirrhosis: a 2020 update. Blood Transfusion, 2021, 19, 9-13.	0.4	4
38	Clinical value of asterixis in 374 well-characterised patients with cirrhosis and varying degree of hepatic encephalopathy. Digestive and Liver Disease, 2020, 52, 235-236.	0.9	2
39	Safety of two different doses of simvastatin plus rifaximin in decompensated cirrhosis (LIVERHOPE-SAFETY): a randomised, double-blind, placebo-controlled, phase 2 trial. The Lancet Gastroenterology and Hepatology, 2020, 5, 31-41.	8.1	75
40	Efficacy of Albumin Treatment for Patients with CirrhosisÂandÂInfections Unrelated to Spontaneous BacterialÂPeritonitis. Clinical Gastroenterology and Hepatology, 2020, 18, 963-973.e14.	4.4	77
41	Including Relative Adrenal Insufficiency in Definition and Classification of Acute-on-Chronic Liver Failure. Clinical Gastroenterology and Hepatology, 2020, 18, 1188-1196.e3.	4.4	39
42	Fam20Câ€mediated phosphorylation of osteopontin is critical for its secretion but dispensable for its action as a cytokine in the activation of hepatic stellate cells in liver fibrogenesis. FASEB Journal, 2020, 34, 1122-1135.	0.5	6
43	ERP correlates of cognitive control and food-related processing in normal weight and severely obese candidates for bariatric surgery: Data gathered using a newly designed Simon task. Biological Psychology, 2020, 149, 107804.	2.2	3
44	The reasons for my application. Journal of Hepatology, 2020, 72, 5-7.	3.7	0
45	Mitochondria-targeted antioxidant mitoquinone attenuates liver inflammation and fibrosis in cirrhotic rats. American Journal of Physiology - Renal Physiology, 2020, 318, G298-G304.	3.4	42
46	Reply to: â€œLack of evidence for a continuum between hepatorenal syndrome and acute tubular necrosisâ€• Journal of Hepatology, 2020, 72, 582-583.	3.7	2
47	Blood metabolomics uncovers inflammation-associated mitochondrial dysfunction as a potential mechanism underlying ACLF. Journal of Hepatology, 2020, 72, 688-701.	3.7	223
48	PCSK9 Levels Are Raised in Chronic HCV Patients with Hepatocellular Carcinoma. Journal of Clinical Medicine, 2020, 9, 3134.	2.4	19
49	The PREDICT study uncovers three clinical courses of acutely decompensated cirrhosis that have distinct pathophysiology. Journal of Hepatology, 2020, 73, 842-854.	3.7	282
50	Introducing the Expert Opinion series. Journal of Hepatology, 2020, 73, 5.	3.7	4
51	Albumin in decompensated cirrhosis: new concepts and perspectives. Gut, 2020, 69, 1127-1138.	12.1	190
52	Effect of Morning Light Glasses and Night Short-Wavelength Filter Glasses on Sleep-Wake Rhythmicity in Medical Inpatients. Frontiers in Physiology, 2020, 11, 5.	2.8	10
53	Expectancy to Eat Modulates Cognitive Control and Attention Toward Irrelevant Food and Non-food Images in Healthy Starving Individuals. A Behavioral Study. Frontiers in Psychology, 2020, 11, 569867.	2.1	0
54	Statins: Old drugs as new therapy for liver diseases?. Journal of Hepatology, 2019, 70, 194-202.	3.7	108

#	Article	IF	Citations
55	The first Chinese guidelines on the Management of Ascites and its Related Complications in Cirrhosis: a great goal for a great country. Hepatology International, 2019, 13, 395-398.	4.2	1
56	News in pathophysiology, definition and classification of hepatorenal syndrome: A step beyond the International Club of Ascites (ICA) consensus document. Journal of Hepatology, 2019, 71, 811-822.	3.7	272
57	PS-083-Serum albumin concentration as guide for long-term albumin treatment in patients with cirrhosis and uncomplicated ascites: Lessons from the ANSWER study. Journal of Hepatology, 2019, 70, e53.	3.7	5
58	Current Concepts on Bacterial and Fungal Infections in Cirrhosis. Clinical Liver Disease, 2019, 14, 87-91.	2.1	5
59	The psychomotor vigilance task: Role in the diagnosis of hepatic encephalopathy and relationship with driving ability. Journal of Hepatology, 2019, 70, 648-657.	3.7	13
60	Predictive value of induced hyperammonaemia and neuropsychiatric profiling in relation to the occurrence of post-TIPS hepatic encephalopathy. Metabolic Brain Disease, 2019, 34, 1803-1812.	2.9	8
61	Morbidity and mortality after transjugular intrahepatic portosystemic shunt placement in patients with cirrhosis. European Journal of Gastroenterology and Hepatology, 2019, 31, 626-632.	1.6	18
62	Recommendations on the Diagnosis and Initial Management of Acute Variceal Bleeding and Hepatorenal Syndrome in Patients with Cirrhosis. Digestive Diseases and Sciences, 2019, 64, 1419-1431.	2.3	9
63	Reply to: â€œProphylaxis of spontaneous bacterial peritonitis: is there still room for quinolones?â€• Journal of Hepatology, 2019, 70, 1028-1030.	3.7	2
64	Predicting Outcomes of Liver Transplantation in Patients With Nonalcoholic Steatohepatitis: Pretransplant Renal Function Is Key. Liver Transplantation, 2019, 25, 362-364.	2.4	1
65	The influence ofHEhistory,HEstatus and neuropsychological test type on learning ability in patients with cirrhosis. Liver International, 2019, 39, 861-870.	3.9	3
66	Effects of Albumin Treatment on Systemic and Portal Hemodynamics and Systemic Inflammation in Patients With Decompensated Cirrhosis. Gastroenterology, 2019, 157, 149-162.	1.3	178
67	Outcome of a First Episode of Bacterial Infection in Candidates for Liver Transplantation. Liver Transplantation, 2019, 25, 1187-1197.	2.4	5
68	Addressing Profiles of Systemic Inflammation Across the Different Clinical Phenotypes of Acutely Decompensated Cirrhosis. Frontiers in Immunology, 2019, 10, 476.	4.8	134
69	Epidemiology and Effects of Bacterial Infections in Patients With Cirrhosis Worldwide. Gastroenterology, 2019, 156, 1368-1380.e10.	1.3	296
70	Serum Squamous Cell Carcinoma Antigen-Immunoglobulin M complex levels predict survival in patients with cirrhosis. Scientific Reports, 2019, 9, 20126.	3.3	6
71	Longâ€term administration of human albumin improves survival in patients with cirrhosis and refractory ascites. Liver International, 2019, 39, 98-105.	3.9	100
72	Multidrug-resistant bacterial infections in patients with decompensated cirrhosis and with acute-on-chronic liver failure in Europe. Journal of Hepatology, 2019, 70, 398-411.	3.7	225

#	Article	IF	Citations
73	Orchestration of Tryptophanâ€Kynurenine Pathway, Acute Decompensation, and Acuteâ€onâ€Chronic Liver Failure in Cirrhosis. Hepatology, 2019, 69, 1686-1701.	7.3	80
74	EASL Clinical Practice Guidelines for the management of patients with decompensated cirrhosis. Journal of Hepatology, 2018, 69, 406-460.	3.7	1,762
75	Association Between Grade of Acute on Chronic Liver Failure and Response to Terlipressin and Albumin in PatientsÂWith Hepatorenal Syndrome. Clinical Gastroenterology and Hepatology, 2018, 16, 1792-1800.e3.	4.4	127
76	Infections complicating cirrhosis. Liver International, 2018, 38, 126-133.	3.9	122
77	Newly diagnosed hepatocellular carcinoma in patients with advanced hepatitis C treated with DAAs: A prospective population study. Journal of Hepatology, 2018, 69, 345-352.	3.7	128
78	Assessment of Sepsis-3 criteria and quick SOFA in patients with cirrhosis and bacterial infections. Gut, 2018, 67, 1892-1899.	12.1	98
79	Management of ascites and hepatorenal syndrome. Hepatology International, 2018, 12, 122-134.	4.2	62
80	Cardiovascular predictors of death in patients with cirrhosis. Hepatology, 2018, 68, 215-223.	7.3	41
81	Acute-on-Chronic Liver Failure: From Basic Research to Clinical Applications. Canadian Journal of Gastroenterology and Hepatology, 2018, 2018, 1-3.	1.9	3
82	Hepatorenal syndrome. Nature Reviews Disease Primers, 2018, 4, 23.	30.5	172
83	Changes in Accident & Emergency Visits and Return Visits in Relation to the Enforcement of Daylight Saving Time and Photoperiod. Journal of Biological Rhythms, 2018, 33, 555-564.	2.6	15
84	Long-term albumin administration in decompensated cirrhosis (ANSWER): an open-label randomised trial. Lancet, The, 2018, 391, 2417-2429.	13.7	345
85	Renal Function in Cirrhosis: A Critical Review of Available Tools. Seminars in Liver Disease, 2018, 38, 230-241.	3.6	37
86	Why and how to measure renal function in patients with liver disease. Liver International, 2017, 37, 116-122.	3.9	35
87	Reply to: â€œTools and tactics for improving diagnosis of hepatic encephalopathyâ€. Journal of Hepatology, 2017, 66, 1328-1329.	3.7	0
88	The animal naming test: An easy tool for the assessment of hepatic encephalopathy. Hepatology, 2017, 66, 198-208.	7.3	135
89	Liver Retransplantation for Hepatic Abscess Due to Hepatic Artery Thrombosis: A Case Report. Transplantation Proceedings, 2017, 49, 736-739.	0.6	0
90	Screening studies of transient elastography and FibroTest in the general population â€“ Authors' reply. The Lancet Gastroenterology and Hepatology, 2017, 2, 246-247.	8.1	0

#	Article	IF	Citations
91	Neuropsychiatric performance in patients with cirrhosis: Who is â€œnormalâ€?. Journal of Hepatology, 2017, 66, 825-835.	3.7	15
92	Predictors of Early Readmission in Patients With Cirrhosis After the Resolution of Bacterial Infections. American Journal of Gastroenterology, 2017, 112, 1575-1583.	0.4	28
93	Incidence, predictors and outcomes of acute-on-chronic liver failure in outpatients with cirrhosis. Journal of Hepatology, 2017, 67, 1177-1184.	3.7	101
94	Abnormalities in the 24â€hour rhythm of skin temperature in cirrhosis: Sleepâ€wake and general clinical implications. Liver International, 2017, 37, 1833-1842.	3.9	39
95	New diagnostic criteria and management of acute kidney injury. Journal of Hepatology, 2017, 66, 860-861.	3.7	35
96	Consensus conference on TIPS management: Techniques, indications, contraindications. Digestive and Liver Disease, 2017, 49, 121-137.	0.9	111
97	Validation of a Staging System for Acute Kidney Injury in Patients With Cirrhosis and Association With Acute-on-Chronic Liver Failure. Clinical Gastroenterology and Hepatology, 2017, 15, 438-445.e5.	4.4	125
98	The impact of infection by multidrugâ€resistant agents in patients with cirrhosis. A multicenter prospective study. Liver International, 2017, 37, 71-79.	3.9	57
99	Limited Efficacy of Tolvaptan in Patients with Cirrhosis and Severe Hyponatremia: Real-Life Experience. American Journal of Medicine, 2017, 130, 372-375.	1.5	31
100	Occult liver disease burden: Analysis from a large general practitionersâ€™ database. United European Gastroenterology Journal, 2017, 5, 982-986.	3.8	12
101	Inhibition of epoxyeicosatrienoic acid production in rats with cirrhosis has beneficial effects on portal hypertension by reducing splanchnic vasodilation. Hepatology, 2016, 64, 923-930.	7.3	18
102	The empirical antibiotic treatment of nosocomial spontaneous bacterial peritonitis: Results of a randomized, controlled clinical trial. Hepatology, 2016, 63, 1299-1309.	7.3	186
103	Terlipressin given by continuous intravenous infusion versus intravenous boluses in the treatment of hepatorenal syndrome: A randomized controlled study. Hepatology, 2016, 63, 983-992.	7.3	225
104	A lowâ€cost, userâ€friendly electroencephalographic recording system for the assessment of hepatic encephalopathy. Hepatology, 2016, 63, 1651-1659.	7.3	29
105	Reply. Hepatology, 2016, 64, 318-318.	7.3	1
106	Lack of consensus for usage of Î²-blockers in end-stage liver disease. Gut, 2016, 65, 1058-1060.	12.1	8
107	Brexit from current guideline recommendations?. Gut, 2016, 65, 1919.1-1919.	12.1	1
108	Screening for liver fibrosis in the general population: a call for action. The Lancet Gastroenterology and Hepatology, 2016, 1, 256-260.	8.1	131

#	Article	IF	Citations
109	Systemic inflammation in decompensated cirrhosis: Characterization and role in acuteâ€onâ€chronic liver failure. Hepatology, 2016, 64, 1249-1264.	7.3	550
110	Reply. Hepatology, 2016, 64, 2268-2269.	7.3	0
111	Reply. Hepatology, 2016, 64, 2260-2262.	7.3	0
112	Vigilance and wake EEG architecture in simulated hyperammonaemia: a pilot study on the effects of L-Ornithine-L-Aspartate (LOLA) and caffeine. Metabolic Brain Disease, 2016, 31, 965-974.	2.9	8
113	Cardiac Remodeling in Patients With Primary and Secondary Aldosteronism. Circulation: Cardiovascular Imaging, 2016, 9, .	2.6	41
114	Reply. Hepatology, 2016, 64, 998-999.	7.3	4
115	Neutrophil gelatinase-associated lipocalin is a biomarker of acute-on-chronic liver failure and prognosis in cirrhosis. Journal of Hepatology, 2016, 65, 57-65.	3.7	112
116	Squamous cell carcinoma antigen-IgM is associated with hepatocellular carcinoma in patients with cirrhosis: A prospective study. Digestive and Liver Disease, 2016, 48, 197-202.	0.9	14
117	Management of the critically ill patient with cirrhosis: A multidisciplinary perspective. Journal of Hepatology, 2016, 64, 717-735.	3.7	243
118	Sepsis-induced acute kidney injury in patients with cirrhosis. Hepatology International, 2016, 10, 115-123.	4.2	36
119	AISF-SIMTI position paper: the appropriate use of albumin in patients with liver cirrhosis. Blood Transfusion, 2016, 14, 8-22.	0.4	13
120	Hepatic decompensation in the absence of obvious precipitants: the potential role of cytomegalovirus infection/reactivation. BMJ Open Gastroenterology, 2015, 2, e000050.	2.7	8
121	Clinical Course of acuteâ€onâ€chronic liver failure syndrome and effects on prognosis. Hepatology, 2015, 62, 243-252.	7.3	493
122	Is type 2 hepatorenal syndrome still a potential indication for treatment with terlipressin and albumin?. Liver Transplantation, 2015, 21, 1335-1337.	2.4	2
123	Dopamine and Furosemide for the Treatment of Hepatorenal Syndrome: A Reappraisal or Just Smoke and Mirrors?. Journal of Clinical and Experimental Hepatology, 2015, 5, 273-275.	0.9	4
124	Diagnosis and management of acute kidney injury in patients with cirrhosis: revised consensus recommendations of the International Club of Ascites. Gut, 2015, 64, 531-537.	12.1	405
125	Reply to: â€œA cut-off serum creatinine value of 1.5 mg/dl for AKI â€“ To be or not to beâ€. Journal of Hepatology, 2015, 62, 744-746.	3.7	4
126	Terlipressin plus albumin versus midodrine and octreotide plus albumin in the treatment of hepatorenal syndrome: A randomized trial. Hepatology, 2015, 62, 567-574.	7.3	283

#	Article	IF	Citations
127	Diagnosis and management of acute kidney injury in patients with cirrhosis: Revised consensus recommendations of the International Club of Ascites. Journal of Hepatology, 2015, 62, 968-974.	3.7	571
128	The CLIF Consortium Acute Decompensation score (CLIF-C ADs) for prognosis of hospitalised cirrhotic patients without acute-on-chronic liver failure. Journal of Hepatology, 2015, 62, 831-840.	3.7	289
129	Mechanisms of decompensation and organ failure in cirrhosis: From peripheral arterial vasodilation to systemic inflammation hypothesis. Journal of Hepatology, 2015, 63, 1272-1284.	3.7	463
130	New <scp>ICA</scp> criteria for the diagnosis of acute kidney injury in cirrhotic patients: can we use an imputed value of serum creatinine?. Liver International, 2015, 35, 2108-2114.	3.9	33
131	Managing complications in cirrhotic patients. United European Gastroenterology Journal, 2015, 3, 80-94.	3.8	9
132	Acute kidney injury and acute-on-chronic liver failure classifications in prognosis assessment of patients with acute decompensation of cirrhosis. Gut, 2015, 64, 1616-1622.	12.1	86
133	Reply to: â€œCoordinated care models in cirrhosis; the need for further randomized controlled trialsâ€. Journal of Hepatology, 2014, 60, 466-467.	3.7	0
134	Characteristics, risk factors, and mortality of cirrhotic patients hospitalized for hepatic encephalopathy with and without acute-on-chronic liver failure (ACLF). Journal of Hepatology, 2014, 60, 275-281.	3.7	259
135	Bacterial infections in cirrhosis: A position statement based on the EASL Special Conference 2013. Journal of Hepatology, 2014, 60, 1310-1324.	3.7	685
136	Development and validation of a prognostic score to predict mortality in patients with acute-on-chronic liver failure. Journal of Hepatology, 2014, 61, 1038-1047.	3.7	741
137	Reply to: â€œTo close the stable door before the horse has boltedâ€. Journal of Hepatology, 2014, 60, 680-681.	3.7	1
138	Early markers of neural dysfunction and compensation: A model from minimal hepatic encephalopathy. Clinical Neurophysiology, 2014, 125, 1138-1144.	1.5	6
139	Covert Hepatic Encephalopathy: Does the Mini-Mental State Examination Help?. Journal of Clinical and Experimental Hepatology, 2014, 4, 89-93.	0.9	12
140	Covert hepatic encephalopathy: Agreement and predictive validity of different indices. World Journal of Gastroenterology, 2014, 20, 15756.	3.3	50
141	How to improve care in outpatients with cirrhosis and ascites: A new model of care coordination by consultant hepatologists. Journal of Hepatology, 2013, 59, 257-264.	3.7	146
142	Evaluation of the Acute Kidney Injury Network criteria in hospitalized patients with cirrhosis and ascites. Journal of Hepatology, 2013, 59, 482-489.	3.7	232
143	Terlipressin for the treatment of hepatorenal syndrome in patients with cirrhosis. Expert Opinion on Orphan Drugs, 2013, 1, 241-248.	0.8	1
144	Positive cardiac inotropic effect of albumin infusion in rodents with cirrhosis and ascites: molecular mechanisms. Hepatology, 2013, 57, 266-276.	7.3	104

#	Article	IF	Citations
145	Acute-on-Chronic Liver Failure Is a Distinct Syndrome That Develops in Patients With Acute Decompensation of Cirrhosis. Gastroenterology, 2013, 144, 1426-1437.e9.	1.3	2,211
146	Current limits and future challenges in the management of renal dysfunction in patients with cirrhosis: report from the <scp>I</scp>nternational <scp>C</scp>lub of <scp>A</scp>scites. Liver International, 2013, 33, 16-23.	3.9	63
147	Current management of uncomplicated ascites. Clinical Liver Disease, 2013, 2, 125-127.	2.1	0
148	Hepatorenal syndrome, MELD score and liver transplantation: An evolving issue with relevant implications for clinical practice. Journal of Hepatology, 2012, 57, 1135-1140.	3.7	87
149	Optimal management of hepatorenal syndrome in patients with cirrhosis. Hepatic Medicine: Evidence and Research, 2010, 2, 87.	2.5	13
150	Combined versus sequential diuretic treatment of ascites in non-azotaemic patients with cirrhosis: results of an open randomised clinical trial. Gut, 2010, 59, 98-104.	12.1	122
151	Pathogenesis and management of hepatorenal syndrome in patients with cirrhosis. Journal of Hepatology, 2008, 48, S93-S103.	3.7	94
152	Detection of minimal hepatic encephalopathy: Normalization and optimization of the Psychometric Hepatic Encephalopathy Score. A neuropsychological and quantified EEG study. Journal of Hepatology, 2008, 49, 346-353.	3.7	175
153	Nephrotoxicity of intravenous immunoglobulin in the setting of liver transplantation or HBV-related cirrhosis: an undervalued topic. Minerva Gastroenterologica E Dietologica, 2008, 54, 259-75.	2.2	5
154	Switch therapy with ciprofloxacin vs. intravenous ceftazidime in the treatment of spontaneous bacterial peritonitis in patients with cirrhosis: similar efficacy at lower cost. Alimentary Pharmacology and Therapeutics, 2006, 23, 75-84.	3.7	70
155	Hyponatremia in cirrhosis: Results of a patient population survey. Hepatology, 2006, 44, 1535-1542.	7.3	349
156	The role of nitric oxide in the pathogenesis of systemic and splanchnic vasodilation in cirrhotic rats before and after the onset of ascites. Liver International, 2005, 25, 429-437.	3.9	35
157	Prognosis of hepatorenal syndrome â€“ has it changed with current practice?. Alimentary Pharmacology and Therapeutics, 2004, 20, 44-46.	3.7	17
158	The management of ascites in cirrhosis: Report on the consensus conference of the International Ascites Club. Hepatology, 2003, 38, 258-266.	7.3	744
159	Increased activity of guanosine 3â€²-5â€²-cyclic monophosphate phosphodiesterase in the renal tissue of cirrhotic rats with ascites. Hepatology, 2000, 31, 304-310.	7.3	18
160	Clinical features and survivial of cirrhotic patients with subclinical cognitive alterations detected by the number connection test and computerized psychometric tests. Hepatology, 1999, 29, 1662-1667.	7.3	230
161	Reversal of type 1 hepatorenal syndrome with the administration of midodrine and octreotide. Hepatology, 1999, 29, 1690-1697.	7.3	526
162	Acute effects of the oral administration of midodrine, an ?-adrenergic agonist, on renal hemodynamics and renal function in cirrhotic patients with ascites. Hepatology, 1998, 28, 937-943.	7.3	131

#	Article	IF	Citations
163	Q-T Interval Prolongation in Liver Cirrhosis. Reversibility after Orthotopic Liver Transplantation.. International Heart Journal, 1998, 39, 321-329.	0.6	37
164	Hemodynamic evaluation of the addition of isosorbide-5-mononitrate to nadolol in cirrhotic patients with insufficient response to the ?- blocker alone. Hepatology, 1997, 26, 34-39.	7.3	294
165	Randomized trial comparing albumin, dextran 70, and polygeline in cirrhotic patients with ascites treated by paracentesis. Gastroenterology, 1996, 111, 1002-1010.	1.3	528
166	Malnutrition in alcoholic and virus-related cirrhosis. American Journal of Clinical Nutrition, 1996, 63, 602-609.	4.7	242
167	Cirrhosis and muscle cramps: Evidence of a causal relationship. Hepatology, 1996, 23, 264-273.	7.3	124
168	Long-term effect of nadolol or nadolol plus isosorbide-5-mononitrate on renal function and ascites formation in patients with cirrhosis. Hepatology, 1995, 22, 808-813.	7.3	30
169	Role of nitric oxide and prostacyclin in the control of renal perfusion in experimental cirrhosis. Hepatology, 1995, 22, 915-920.	7.3	65
170	Randomized clinical study of the efficacy of amiloride and potassium canrenoate in nonazotemic cirrhotic patients with ascites. Hepatology, 1994, 19, 72-79.	7.3	100
171	Randomized clinical study of the efficacy of amiloride and potassium canrenoate in nonazotemic cirrhotic patients with ascites. Hepatology, 1994, 19, 72-79.	7.3	5
172	Randomized clinical study of the efficacy of amiloride and potassium canrenoate in nonazotemic cirrhotic patients with ascites. Hepatology, 1994, 19, 72-9.	7.3	27
173	Renal vasoconstriction in cirrhosis evaluated by duplex doppler ultrasonography. Hepatology, 1993, 17, 219-224.	7.3	100
174	Effects of amiloride on renal lithium handling in nonazotemic ascitic cirrhotic patients with avid sodium retention. Hepatology, 1992, 15, 651-654.	7.3	23
175	Variability of atrial natriuretic peptide plasma levels in ascitic cirrhotics: Pathophysiological and clinical implications. Hepatology, 1992, 16, 1389-1394.	7.3	26
176	A pathophysiological interpretation of unresponsiveness to spironolactone in a stepped-care approach to the diuretic treatment of ascites in nonazotemic cirrhotic patients. Hepatology, 1991, 14, 231-236.	7.3	85
177	A pathophysiological interpretation of unresponsiveness to spironolactone in a stepped-care approach to the diuretic treatment of ascites in nonazotemic cirrhotic patients. Hepatology, 1991, 14, 231-236.	7.3	9
178	Comparison of sublingual captopril and nifedipine in immediate treatment of hypertensive emergencies. A randomized, single-blind clinical trial. Archives of Internal Medicine, 1991, 151, 678-82.	3.8	12
179	Hemodynamic changes of systemic, hepatic, and splenic circulation following triglycyl-lysin-vasopressin administration in alcoholic cirrhosis. Digestive Diseases and Sciences, 1988, 33, 1103-1109.	2.3	43